On
September 25th, YM Bioscience presented a poster presentation at the ECCO-EMSO meeting in Stockholm, Sweden regarding the combined use of Nimotuzamab and vinorelbine with radiation in pediatric DIPG entitled:
"Nimotuzumab and Vinorelbine Concomitantly to Radiation and as Maintenance for Diffuse Pontine Glioma in Childhood: Promising Results on a Series of 13 Patients"
http://www.news-medical.net/news/20110927/Data-from-YM-BioSciences-nimotuzumab-clinical-trials-to-be-reported-at-ECCO-ESMO-2011.aspx
This appears to a companion to the 2011 ASCO presentation in Chicago. In this study, the Italian researchers reported on a series of 12 children. They noted that all children were treated on an outpatient basis and none had suffered significant treatment related side effects. For the 12 children (ages from 3-13), the progression free survival at 9 months was 69 ± 21% and the 12 month overall survival
was 81.5 ± 12 %.
The researchers believed this combination shows promise for DIPG
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=77258
Many researchers feel that combination therapy is going to be important in combating DIPG. It is exciting to see the combination therapy research.
